# A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

Source: https://onco.cc/trials/nct05334823/  
OnCo record `nct05334823` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of pCAR-19B cells in acute lymphoblastic leukaemia and childhood cancers, run by Chongqing Precision Biotech Co., Ltd, now recruiting.

## Summary

A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents is a phase 2 interventional study registered as NCT05334823 by Chongqing Precision Biotech Co., Ltd, with 100 participants planned, started 2022-01-26 and due to reach its primary completion in 2028-12-31. Interventions recorded: pCAR-19B cells.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05334823
- Phase: 2
- Setting: A Phase II Clinical Study of Anti-CD19 CAR-T Therapy (pCAR-19B) in the Treatment of CD19-positive Relapsed/Refractory B-ALL
- Sponsor: Chongqing Precision Biotech Co., Ltd
- Enrolled: 100

## Sources

- ClinicalTrials.gov NCT05334823: https://clinicaltrials.gov/study/NCT05334823

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- companies: [Chongqing Precision Biotech](https://onco.cc/companies/chongqing-precision-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct05334823.json